SEFA-1024

Small molecule

Also known as NST-1024

Partialdesign only

Evidence outlook · results not reported

NCT05889156 · High Triglycerides

The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.

NCT05889156: The trial is randomized and blinded with a placebo comparator and measures triglyceride change, the standard disease-defining outcome for this condition, but no results are posted yet, so whether the drug lowered triglycerides is still unknown.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
Phase 1 (2)
Other / comorbidity
NCT05368831 · NorthSea Therapeutics B.V.
2022-07-19 – 2022-09-07 · Healthy Volunteers
What this study did
NCT04630366 · NorthSea Therapeutics B.V.
2020-10-27 – 2022-06-20 · Hypertriglyceridemia
What this study did

Competitive landscape

This drug's own stage for Severe Hypertriglyceridemia: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SEFA-1024: this drugStage not on recordSmall moleculeHepatic triglyceride/VLDL synthesis pathwayPartial signalNo reviewed efficacy summary in this indication
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3)
Olezarsen (Tryngolza)ApprovedRNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Omega-3-Acid Ethyl Esters (Lovaza)ApprovedSmall moleculeTriglyceride metabolismnot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
DR10624Phase 3Protein / enzyme therapeuticGLP-1R; GCGR; FGF21RPartial signal
NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistPartial signalNo reviewed efficacy summary in this indication
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signal
NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67)
NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87)
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signalNo reviewed efficacy summary in this indication
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAPartial signal
NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2)
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SolbinsiranPhase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication
CTX310Phase 1Gene therapy / editingANGPTL3not yet gradedNo reviewed efficacy summary in this indication
GC304
Phase 1(overall)
Gene or cell therapy (subtype unspecified)LPL (lipoprotein lipase) genenot yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.